Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melan…
USD109.86-2.05%vs prev. close
Performance
1W
+4.61%
1M
+26.84%
3M
-5.31%
1Y
+12.19%
YTD
+2.63%
Valuation
P/E
—
EPS TTM
-2.91
Dividend yield
—
Size and risk
Market cap
$7.6B
Beta
2.13
Price history
RYTM price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Rhythm Pharmaceuticals
RYTM
Biotechnology
Mkt cap (USD bn)
7.6
P/E
—
Div yld
—
1W
+4.6%
1M
+26.8%
3M
-5.3%
6M
+17.3%
1Y
+12.2%
YTD
+2.6%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Rhythm Pharmaceuticals
RYTM
Biotechnology
7.6
—
—
+4.6%
+26.8%
-5.3%
+17.3%
+12.2%
+2.6%
Subscribe to Equity Analytics to compare RYTM with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.